AMAM:NYE-Ambrx Biopharma Inc (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 21.60

Change

0.00 (0.00)%

Market Cap

USD 0.70B

Volume

0.06M

Avg Analyst Target

USD 33.43 (+54.78%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Ambrx Biopharma Inc., a clinical-stage biologics company, focuses on discovering and developing engineered precision biologics (EPBs) using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 ADC, which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction (GEJ) cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug (IND)-enabling studies for the treatment of renal cell carcinoma (RCC) and other cancers, as well as other multiple product candidates targeting immuno-oncology applications. In addition, it is developing ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell; and ARX822, a fab-small molecule bispecific that is in preclinical development for cancers. The company has license agreements with NovoCodex, Bristol Myers Squibb Company, Agensys, Inc., Sino Biopharmaceutical Co., Ltd., University of California, BeiGene, Ltd., The Scripps Research Institute and The California Research Institute of Biomedical Research, AbbVie Inc., Astellas Pharma Inc., and Elanco Animal Health. Ambrx Biopharma Inc. was founded in 2003 and is based in La Jolla, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

-0.59 (-0.66%)

USD203.75B 30.40 3.38
BHVN Biohaven Pharmaceutical Holdin..

-2.39 (-1.91%)

USD8.15B N/A N/A
RCUS Arcus Biosciences, Inc

+1.29 (+4.07%)

USD2.27B N/A N/A
MYOV Myovant Sciences Ltd

+0.50 (+2.45%)

USD1.87B N/A N/A
ADCT ADC Therapeutics SA

-0.47 (-2.09%)

USD1.76B -99,999.99 N/A
ZYME Zymeworks Inc

-0.84 (-2.27%)

USD1.71B 300.20 N/A
RFL Rafael Holdings, Inc

-1.42 (-2.73%)

USD0.92B N/A N/A
ANVS Annovis Bio, Inc

-3.89 (-3.50%)

USD0.77B -99,999.99 N/A
PFNX Pfenex Inc

N/A

USD0.44B 268.67 63.90
LCTX Lineage Cell Therapeutics, Inc

-0.07 (-2.55%)

USD0.42B 3.63 N/A

ETFs Containing AMAM

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.70B 71% C- 44% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -33.94 93% A 93% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -23.65% 84% B 17% F
Return on Invested Capital 24.74% 86% B 93% A
Return on Assets -8.38% 89% B+ 5% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.03 100% A+ 99% A+
Short Percent 52.59% 4% F 17% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector